These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 39135890)
1. Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma. Körner M; Spohn M; Schüller U; Bockmayr M Oncoimmunology; 2024; 13(1):2386789. PubMed ID: 39135890 [TBL] [Abstract][Full Text] [Related]
2. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas. Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783 [TBL] [Abstract][Full Text] [Related]
3. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology. Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680 [TBL] [Abstract][Full Text] [Related]
4. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas. Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312 [TBL] [Abstract][Full Text] [Related]
5. Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment. Levine AB; Nobre L; Das A; Milos S; Bianchi V; Johnson M; Fernandez NR; Stengs L; Ryall S; Ku M; Rana M; Laxer B; Sheth J; Sbergio SG; Fedoráková I; Ramaswamy V; Bennett J; Siddaway R; Tabori U; Hawkins C Nat Commun; 2024 Jul; 15(1):5790. PubMed ID: 38987542 [TBL] [Abstract][Full Text] [Related]
6. Immunological classification of gliomas based on immunogenomic profiling. Feng Q; Li L; Li M; Wang X J Neuroinflammation; 2020 Nov; 17(1):360. PubMed ID: 33246490 [TBL] [Abstract][Full Text] [Related]
7. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
8. Integrative multi-omics analysis unveils the connection between transcriptomic characteristics associated with mitochondria and the tumor immune microenvironment in lower-grade gliomas. Jiang C; Wu W; Jiang X; Qian K Sci Rep; 2024 Oct; 14(1):23675. PubMed ID: 39390013 [TBL] [Abstract][Full Text] [Related]
9. Qu S; Liu J; Wang H Front Immunol; 2021; 12():648416. PubMed ID: 33889156 [TBL] [Abstract][Full Text] [Related]
10. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951 [TBL] [Abstract][Full Text] [Related]
11. Identification of the immune gene expression signature associated with recurrence of high-grade gliomas. Roura AJ; Gielniewski B; Pilanc P; Szadkowska P; Maleszewska M; Krol SK; Czepko R; Kaspera W; Wojtas B; Kaminska B J Mol Med (Berl); 2021 Feb; 99(2):241-255. PubMed ID: 33215304 [TBL] [Abstract][Full Text] [Related]
12. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response. Tian R; Li Y; Shu M Front Immunol; 2021; 12():797450. PubMed ID: 35069579 [TBL] [Abstract][Full Text] [Related]
13. Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. Tripathi S; Najem H; Dussold C; Pacheco S; Du R; Sooreshjani M; Hurley L; Chandler JP; Stupp R; Sonabend AM; Horbinski CM; Lukas RV; Xiu J; Lopez G; Nicolaides TP; Brown V; Wadhwani NR; Lam SK; James CD; Rao G; Castro MG; Heimberger AB; DeCuypere M J Clin Invest; 2024 Aug; 134(19):. PubMed ID: 39137048 [TBL] [Abstract][Full Text] [Related]
14. Tumor Purity as an Underlying Key Factor in Glioma. Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819 [No Abstract] [Full Text] [Related]
16. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Robinson MH; Vasquez J; Kaushal A; MacDonald TJ; Velázquez Vega JE; Schniederjan M; Dhodapkar K J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788236 [TBL] [Abstract][Full Text] [Related]
17. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy. Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q Front Immunol; 2021; 12():731751. PubMed ID: 34603309 [TBL] [Abstract][Full Text] [Related]
18. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients. Hu Y; Tu Z; Lei K; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238 [TBL] [Abstract][Full Text] [Related]
19. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma. Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD Front Immunol; 2021; 12():668391. PubMed ID: 34539622 [TBL] [Abstract][Full Text] [Related]
20. A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. Ho CY; Mobley BC; Gordish-Dressman H; VandenBussche CJ; Mason GE; Bornhorst M; Esbenshade AJ; Tehrani M; Orr BA; LaFrance DR; Devaney JM; Meltzer BW; Hofherr SE; Burger PC; Packer RJ; Rodriguez FJ Acta Neuropathol; 2015 Oct; 130(4):575-85. PubMed ID: 26264609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]